The Genomics England board oversees all of our activities, ratifies all major decisions and sets the overall strategy for the organisation. Genomics England has several independent advisory committees that report to the board. These include the Ethics Advisory Committee, Science Advisory Committee, Data Advisory Committee, Access Review Committee, GeCIP Board and the Audit Committee.

Meet the Board

Sir John is a Cambridge graduate who started work in the automobile industry. His career took flight when he founded CAP Scientific Ltd, which grew rapidly to become a core part of the CAP Group plc and subsequently the Sema Group plc of which he was UK Managing Director.

He was then asked by the government to take on the transformation of its defence research laboratories into a commercial organisation. In due course these became an internationally successful technology services company and were floated on the LSE as QinetiQ Group plc of which Sir John became Chairman in 2006.

At the same time he was asked to take the Chair of the Medical Research Council and in 2009 he also took the Chair of Nesta. Sir John retired from QinetiQ in February 2010.

Sir John is a past president of the IET and holds a number of honorary Doctorates and Fellowships, including the Royal Academy of Engineering. He was knighted in 1999.


Mark graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital (Barts) where he developed a research programme in molecular genetics of hypertension and clinical research. In 2009 he won the Lily Prize of the British Pharmacology Society. He is a Fellow of The Royal College of Physicians.

In 2000 Mark successfully bid for £3.1m to create the Barts and The London Genome Centre at the Queen Mary University of London. Since 2008 he has directed the Barts National Institute of Health Research (NIHR) Cardiovascular Biomedical Research Unit. In 2012 he become Co-Chair of NIHR Comprehensive Research Network Cardiovascular Sub-Speciality Group.

Mark was appointed Director of the William Harvey Research Institute in 2002 and was elected to the Academy of Medical Sciences in 2008. His particular areas of research are Cardiovascular Genomics and Translational Cardiovascular Research and Pharmacology.

From 2009 to 2011 Mark was President of the British Hypertension Society. He has also served on the NICE Guideline Group for hypertension and leads the Joint UK Societies’ Working Group and Consensus on Renal Denervation which he has driven from research into NHS care.

In 2013 he became an NIHR Senior Investigator.


Professor Sir John Bell FRS is Regius Professor of Medicine at Oxford University, and Chairman of the Office for the Strategic Coordination of Health Research. He recently stepped down as President of the Academy of Medical Sciences (2006-2011). As a Rhodes Scholar (1975-78), Sir John undertook his medical training in the UK and then went on to Stanford University, returning to the UK in 1987. His research interests are in the area of autoimmune disease and immunology where he has contributed to the understanding of immune activation in a range of autoimmune diseases. In 1993, he founded the Wellcome Trust Centre for Human Genetics, one of the world’s leading centres for complex trait common disease genetics.

Sir John was responsible for the working party that produced the highly influential Academy of Medical Sciences “Strengthening Clinical Research” report that highlighted the need for the UK to focus some of its attention on developing expertise in translational research. In December 2011, Sir John was appointed one of two UK Life Sciences Champions by the Prime Minister.


Dame Sally became Chief Medical Officer for England and Chief Medical Advisor to the UK Government on 3 March 2010. She retains responsibility for Research and Development, and is the Chief Scientific Adviser for the Department of Health.

Dame Sally is independent advisor to the Government on medical matters, with particular responsibilities regarding Public Health. She provides professional leadership for Directors of Public Health and will lead a public health professional network for those responsible for public health services. She is professional head of the Department’s medical staff and head of the Medical Civil service.

Sally has been actively involved in NHS R&D from its establishment and founded the National Institute for Health Research (NIHR) with a budget of £1 billion.

Sally has led UK delegations to WHO summits and forums since 2004 and has played an active role on numerous international committees including WHO Global Advisory Committee on Health Research (ACHR). She has advised many others on research strategy.

Her own research interests focused on sickle cell disease.


Kevin has worked with innovative technology for more than 25 years and in healthcare, research and life sciences for much of that time. Kevin also has experience with large organisations implementing complex information technology in the automotive, high technology and energy sectors. For 14 years he led Cisco’s innovation team focused on healthcare and life sciences. In that role he worked on eHealth strategy and implementation with policy makers, care providers, payer organizations and technology partners at local, regional and national levels in health systems – in the UK and across Europe. Kevin managed a team working globally including with the WHO and European Commission, as well as in China, the USA and Africa. Kevin has advised and supported a large range of NHS bodies on their use of information, innovation and information technology, including the National Institute for Health Research (NIHR) from its inception, NICE, and the Department of Health.

Kevin now supports a range of organisations with their innovation strategies, research into the impact of innovation in heath, and implementation of leading-edge information, communication and collaboration technology. In November 2013 the Health Services Journal (HSJ) named Kevin as one of the top 50 innovators in healthcare.

Kevin is a Visiting Professor at the Maersk Moller McKinney Institute, University of South Denmark, and an Honorary Research Fellow at City University, London. He is a Fellow of BCS, The Chartered Institute of IT, where he has been a member of the Healthcare Policy & Strategy Board, and he is a Fellow of the Royal Society of Medicine.


Sir Malcolm is Chair of the NHS England Board. He is also a barrister and a member of the Bench of Middle Temple. As an academic lawyer he specialised in planning, property and environmental law, and was Professor of Land Economy at Cambridge from 1991-2003. From 2003-2013 he was the President and Provost of UCL (University College London). He has served as Chair of the Local Government Commission for England, of the Agriculture and Environmental Biotechnology Commission and the Russell Group.

He is currently a trustee of Somerset House, a director of Genomics England Ltd; a board member of the University Grants Committee of Hong Kong; and a UK Business Ambassador. He is Chancellor-Elect of the University of York.


Michael is Professor of Bioethics and Director of the Ethox Centre at the University of Oxford. He is a member of the Nuffield Council of Bioethics Working Group on the collection, linking, use and exploitation of biological and health data, the Data Access Committee of the Wellcome Trust Case-Control Consortium, and the Medical Research Council’s Ethics, Regulation and Public Involvement Committee.

He is also an ethics consultant to UK Biobank. He has previously been a member of a number of national and international committees and working parties including the Ethics in Practice Committee of the Royal College of Physicians and the Department of Health’s Committee for the Ethical Aspects of Pandemic Influenza. Michael chairs Genomics England’s Ethics Advisory Committee.


Jonathan Symonds, CBE, was appointed as an independent non-executive Director of HSBC Holdings plc in April 2014. He has extensive international financial and governance experience. Mr Symonds was Chief Financial Officer of Novartis AG from 2009 to 2013. Before joining Novartis he was a Partner and Managing Director of Goldman Sachs (2007-2009); Chief Financial Officer of AstraZeneca plc (1997-2007); and a Partner at KPMG (1992-1997). His governance experience includes roles as non-executive Director and chair of the audit committees of Diageo plc and QinetiQ plc.

He is currently Chairman of Innocoll AG and a non-executive director of Genomics England Limited and of Proteus Digital Health Inc. Mr Symonds is a Fellow of the Institute of Chartered Accountants in England and Wales. He has a BA, First Class Honours in Business Finance from the University of Hertfordshire.


Kay Davies is the Dr Lee’s Professor of Anatomy in the Department of Physiology, Anatomy and Genetics and Director of the MRC Functional Genomics Unit at the University of Oxford. Her research interests lie in the molecular analysis and development of treatment for human genetic disease, particularly, Duchenne muscular dystrophy (DMD) and the application of genomics for the analysis of neurological disorders. She has published more than 400 papers and won numerous awards for her work. She is co-founder of Summit plc which aims to develop a therapy for DMD. She also has an interest in the ethical issues associated with genetics research. She is a founding fellow of the UK Academy of Medical Sciences and was elected a Fellow of the Royal Society in 2003. She has been a Governor of the Wellcome Trust since 2008 and became Deputy Chairman in October, 2013. She was made Dame Commander of the British Empire for services to science in 2008.


Share thisShare on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInEmail this to someone